RALEIGH, N.C., Aug. 25, 2015 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, today announced the promotions of Bekki Brown and Tom Zoda, PhD, to Executive Vice President, Clinical Development, General Medicine and Executive Vice President, Clinical Development, Central Nervous System (CNS), respectively, responsible for providing executive leadership for two of the Company's therapeutic business units. The appointments reinforce INC's continued focus on providing customers with therapeutically specialized project teams to maximize efficiency and collaboration through proven expertise and strong business acumen.
"Having built our organization around our therapeutic depth, we are delighted to appoint Bekki and Tom to further expand our therapeutic offerings in these important and fast-growing market segments," said Michael Gibertini, PhD, President, Clinical Development. "INC is focused on providing specialized teams and experts in particular disciplines that fully understand each therapy area and how to best address customers' needs. By structuring teams in this way, we are able to deliver unique insights that provide a clear advantage in accelerating new therapies to market for the benefit of patients in need."
Brown, who has been with INC Research since 2001, provides global leadership for the Company's General Medicine business unit, which specializes in conducting clinical trials in areas ranging from infectious disease, respiratory disease, immunology and inflammation, gastrointestinal diseases, urology and women's health. Since joining the General Medicine business unit in 2010, she has led operations and guided the group to its highest-ever level of performance. During her tenure at INC, she has made material contributions to the architecture of the Company's Trusted Process® project management methodology. Brown began her career at INC Research in Project Management overseeing CNS studies and has proceeded through the ranks including holding leadership roles in operations management and global training.
Zoda, who has worked in the pharmaceutical and CRO industry for more than 20 years, has extensive experience designing, managing and overseeing clinical trials for the development of CNS therapeutics. He takes over the CNS unit from Gibertini, who now focuses on driving innovation and leveraging efficiencies across all of INC's therapeutic business units for the benefit of customers. Since joining INC Research in 2009, Zoda has directed and overseen large multi-center global trials focused on psychiatric and neurologic indications in areas such as schizophrenia, Alzheimer's Disease, depression, anxiety, multiple sclerosis and epilepsy. He has been instrumental in helping the Company grow its CNS team to more than 900 professionals and in strengthening its position in the marketplace as an industry leader in CNS clinical trials.
INC Research has long-standing therapeutically focused heritage and extensive expertise in a broad range of areas, including CNS, oncology and other complex diseases such as immunology and infectious diseases as well as cardiology, endocrinology, inflammatory diseases, women's health, gastroenterology, dermatology and ophthalmology. From therapeutically-aligned clinical monitors to project managers to senior management, INC experts understand specific therapy challenges, needs and opportunities, which enhances the clinical research process for sites, customers and ultimately, patients.
About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization (CRO) providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industry. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was ranked "Top CRO to Work With" among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, N.C., with operations across six continents and experience spanning more than 100 countries. For more information, please visit www.incresearch.com.
CONTACT: Investor Relations Contact: Ronnie Speight Vice President, Investor Relations Phone: +1 (919) 745-2745 Email: Investor.Relations@incresearch.com Press/Media Contact: Lori Dorer Senior Director, Corporate Communications Phone: +1 (513) 345-1685 Email: Corporate.Communications@incresearch.com